Share
Print
Call Updates
Aug 9, 2023 3:59:35 PM
Call HORIZON-HLTH-2023-DISEASE-03
We recently informed the applicants about the evaluation results for their proposals.
The results of the evaluation are as follows:
Number of proposals submitted (including proposals transferred from or to other calls): 150
Number of inadmissible proposals: 1
Number of ineligible proposals: 1
Number of above-threshold proposals: 63
Total budget requested for above-threshold proposals: EUR 432,892,132.
Apr 13, 2023 6:42:31 PM
Call HORIZON-HLTH-2023-DISEASE-03 closed on 13 April 2023. 150 proposals were submitted. The breakdown per topic is:
HORIZON-HLTH-2023-DISEASE-03-06: 1 proposals
Evaluation results are expected to be communicated on Friday 04 August 2023 at the earliest.
Jan 12, 2023 11:43:07 AM
The submission session is now available for: HORIZON-HLTH-2023-DISEASE-03-06(HORIZON-CSA)
Towards structuring brain health research in Europe
TOPIC ID: HORIZON-HLTH-2023-DISEASE-03-06
Programme: Horizon Europe Framework Programme (HORIZON)
Call: Tackling diseases (Single stage - 2023) (HORIZON-HLTH-2023-DISEASE-03)
Type of action: HORIZON-CSA HORIZON Coordination and Support Actions
Type of MGA: HORIZON Action Grant Budget-Based [HORIZON-AG]
Deadline model: single-stage
Planned opening date: 12 January 2023
Deadline date: 13 April 2023 17:00:00 Brussels time
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to most of the following expected outcomes:
Member States and Associated Countries have agreed to step up their coordination in the area of brain research, which could take the form of a European partnership on Brain Health[2] in the second Strategic Plan of Horizon Europe[3].
Proposals should address all of the following aspects:
This coordination action implies the preparation and organisation of meetings, as well as support to information exchange with relevant stakeholder groups and with the public.
This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.
[1]Other relevant stakeholders include researchers, health care providers and practitioners, patients, citizens, regulators and industry.
[2]In the context of the partnership, ‘brain health’ should be interpreted as a concept that encompasses neural development, neuroplasticity, brain functioning, and recovery across the life course, including mental health and wellbeing elements.
[3]This topic does not pre-judge the content of the second Strategic Plan of Horizon Europe.
[4]Relevant bodies include EU-supported initiatives, scientific and clinical societies, patient organisations, regulators and the industry.
[5]This includes the common research agenda developed by the ‘European Brain Research Area’ (EBRA) project, as well as the strategic research agendas of the partnerships: ‘EU Joint Programme – Neurodegenerative Disease Research’ (JPND), ‘Network of European Funding for Neuroscience Research’ (NEURON), ‘Human Brain Project’ (HBP) and the ‘Innovative Medicines Initiative’ (IMI) and its successor the ‘Innovative Health Initiative’ (IHI).
[6]Global organisations include the World Health Organization (WHO), the Organisation for Economic Co-operation and Development (OECD) and the Global Alliance for Chronic Diseases (GACD).
[7]Entities include the global brain initiatives, the International Initiative for Traumatic Brain Injury Research (InTBIR) and the International Brain Research Organisation (IBRO).
[8]EU-supported infrastructures include, for example, the BBMRI-ERIC infrastructure for biobanking, the EBRAINS research infrastructure, and various platforms developed by the Innovative Medicines Initiative (IMI) and its successor the Innovative Health Initiative (IHI).